aap: Q3/2015 sales with EUR 8.4 million (+7%) in line with expectations; strong quarter in Biomaterials business (+27%)
(Thomson Reuters ONE) -
aap Implantate AG /
aap: Q3/2015 sales with EUR 8.4 million (+7%) in line with expectations; strong
quarter in Biomaterials business (+27%)
. Processed and transmitted by NASDAQ OMX Corporate Solutions.
The issuer is solely responsible for the content of this announcement.
aap Implantate AG (XETRA: AAQ.DE) generated sales of EUR 8.4 million in the
third quarter of 2015 (Q3/2014: EUR 7.8 million) according to preliminary
figures, thereby achieving a result within the August forecast of EUR 7.5
million to EUR 9.0 million. Sales in the first nine months of the current
financial year totalled EUR 22.0 million (9M/2014: EUR 22.1 million).
+-----------------+---------+---------+--------+
| | | | |
| In EUR million | Q3/2015 | Q3/2014 | Change |
+-----------------+---------+---------+--------+
| Sales | 8.4 | 7.8 | 7% |
+-----------------+---------+---------+--------+
| Trauma | 2.9 | 3.3 | -14% |
| | | | |
| thereof LOQTEQ® | 1.5 | 2.4 | -37% |
+-----------------+---------+---------+--------+
| Biomaterials | 5.4 | 4.2 | 27% |
+-----------------+---------+---------+--------+
| Projects | 0.0 | 0.1 | -92% |
+-----------------+---------+---------+--------+
| Other | 0.1 | 0.2 | -30% |
+-----------------+---------+---------+--------+
+-----------------+---------+---------+--------+
| | | | |
| In EUR million | 9M/2015 | 9M/2014 | Change |
+-----------------+---------+---------+--------+
| Sales | 22.0 | 22.1 | 0% |
+-----------------+---------+---------+--------+
| Trauma | 8.5 | 8.4 | 1% |
| | | | |
| thereof LOQTEQ® | 5.2 | 5.3 | -2% |
+-----------------+---------+---------+--------+
| Biomaterials | 13.0 | 12.7 | 2% |
+-----------------+---------+---------+--------+
| Projects | 0.2 | 0.3 | -25% |
+-----------------+---------+---------+--------+
| Other | 0.3 | 0.7 | -59% |
+-----------------+---------+---------+--------+
In the trauma business aap Implantate AG reached sales of EUR 2.9 million
(Q3/2014: EUR 3.3 million) in the third quarter of 2015. The background to this
decline were various developments in our strategically important growth markets
in the BRICS and SMIT countries which weighed perceptibly on demand. Crucial
were in particular a significantly reduced willingness to invest in China as a
consequence of the recent stock market crash and the devaluation of the Chinese
currency, the continuing weak Rouble including the trade sanctions imposed
against Russia as well as the increasing unfavourable development of the
Euro/Turkish Lira exchange rate in connection with a reimbursement reduction
already implemented at the beginning of the year. Furthermore the first
shipments to Brazil which were planned for the third quarter could not be
carried out due to delays in product approval.
Although customer interest in aap Implantate AG's trauma portfolio remains
intact, the company was unable to escape these external developments entirely.
Furthermore, the US market has yet to make a significant contribution toward
sales due to in part protracted administrative processes.
In contrast sales in the biomaterials business rose by 27% year-on-year in the
third quarter of the current financial year to EUR 5.4 million (Q3/2014: EUR
4.2 million). The growth driver in the third quarter of 2015 was in particular
the bone cement business with global leading companies.
In the first nine months of 2015, aap Implantate AG's sales in the trauma
business totalled EUR 8.5 million (9M/2014: EUR 8.4 million). In the
biomaterials business sales totalled EUR 13.0 million (9M/2014: EUR 12.7
million) in the nine-month period 2015.
The preliminary results contained in this press release are based on
management's initial analysis of operations for the period ended on 30 September
2015, and are therefore subject to change. aap Implantate AG plans to announce
its final results for the third quarter respectively the first nine months of
2015 on 13 November 2015.
About aap Implantate AG
aap Implantate AG is a globally operating medical device company headquartered
in Berlin, Germany. The company develops, manufactures and markets trauma and
biomaterials products for orthopedics. The trauma portfolio includes besides the
innovative anatomical plating system LOQTEQ® a wide range of cannulated screws
as well as standard plates and screws. In the biomaterials business the company
is specialized on bone cements and mixing systems. In German-speaking countries
aap Implantate AG directly sells its trauma products to hospitals, buying
syndicates and hospital groups while it uses a broad network of distributors in
more than 60 countries at the international level. In the biomaterials business
sales are handled via OEM and private label cooperations with several selected
international orthopedic and trauma companies. aap Implantate AG's stock is
listed in the Prime Standard segment of Frankfurt Stock Exchange (XETRA:
AAQ.DE). For more information, please visit www.aap.de, or download the
Company's investor relations app from the Apple's App Store or Google Play.
Forward-looking statement
This release may contain forward-looking statements based on current experience,
estimates and projections of the management board and currently available
information. They are not guarantees of future performance. Various known and
unknown risks, uncertainties and other factors could lead to material
differences between the actual future results, financial situation, development
or performance of the company and the estimates given here. Many factors could
cause the actual results, performance or achievements of aap to be materially
different from those that may be expressed or implied by such statements. These
factors include those discussed in aap's public reports. Forward-looking
statements therefore speak only as of the date they are made. aap does not
assume any obligation to update the forward-looking statements contained in this
release or to conform them to future events or developments.
For inquiries please contact: aap Implantate AG, Fabian Franke, Investor
Relations, Lorenzweg 5, 12099 Berlin, Germany
Tel.: +49 30 7501 9-134, fax: +49 30 7501 9-290, e-mail: f.franke(at)aap.de
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: aap Implantate AG via GlobeNewswire
[HUG#1958424]
Unternehmensinformation / Kurzprofil:
Datum: 13.10.2015 - 08:46 Uhr
Sprache: Deutsch
News-ID 426327
Anzahl Zeichen: 7824
contact information:
Town:
Berlin
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 145 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"aap: Q3/2015 sales with EUR 8.4 million (+7%) in line with expectations; strong quarter in Biomaterials business (+27%)"
steht unter der journalistisch-redaktionellen Verantwortung von
aap Implantate AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
